Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Giller who wrote (1148)	4/1/1998 4:37:00 PM
From: WeirdPro Randy	Respond to of 1359

I have been watching CNBC a fair bit, and their knowledge of things tends to be a bit askew at times......yesterday in a feature report they referred to "phen-fen, a combination of Redux and an amphetamine". I think the street looks at this report with some skepticism based on its setup being an average patient use duration of only 76 days, when the reasons behind this was the convenience and "serendipity" of having a group of double-blinded patients who were initially being worked up for a once a day Redux tablet. The street right now is wondering how significant this study is, and even wondering why they even did this study, based on the short term duration of usage even though it does relate with the majority of US Redux users. It is perplexing to them as this does not give good information to the whole picture.......... they are still lumping Redux and phen-fen together. However, with regards to which "study" to believe, other than VERY scanty information collected by the FDA last fall, this is the only study to date of any value, especially relating to Redux. When you put this study up against the rest, it isn't even a fight because there is only one fighter. only one fighter.